Molecular events in neuroendocrine prostate cancer development
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises
de novo only rarely; the disease predominantly develops from adenocarcinoma in response
to drug-induced androgen receptor signalling inhibition, although the mechanisms behind
this transdifferentiation are a subject of debate. The survival of patients with NEPC is poor,
and few effective treatment options are available. To improve clinical outcomes,
understanding of the biology and molecular mechanisms regulating NEPC development is …
de novo only rarely; the disease predominantly develops from adenocarcinoma in response
to drug-induced androgen receptor signalling inhibition, although the mechanisms behind
this transdifferentiation are a subject of debate. The survival of patients with NEPC is poor,
and few effective treatment options are available. To improve clinical outcomes,
understanding of the biology and molecular mechanisms regulating NEPC development is …
Abstract
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises de novo only rarely; the disease predominantly develops from adenocarcinoma in response to drug-induced androgen receptor signalling inhibition, although the mechanisms behind this transdifferentiation are a subject of debate. The survival of patients with NEPC is poor, and few effective treatment options are available. To improve clinical outcomes, understanding of the biology and molecular mechanisms regulating NEPC development is crucial. Various NEPC molecular drivers make temporal contributions during NEPC development, and despite the limited treatment options available, several novel targeted therapeutics are currently under research.
nature.com